X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $6.88 | -1,644 | 10,189 | -14% | -$11,311 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $6.88 | -2,586 | 42,796 | -6% | -$17,792 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Renninger Robert | CFO | S - Sale+OE | $6.88 | -297 | 12,857 | -2% | -$2,043 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale+OE | $6.88 | -876 | 20,681 | -4% | -$6,027 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $6.88 | -876 | 13,978 | -6% | -$6,027 | |||||
2025-12-31 | BEAM | Beam Therapeutics Inc. | Emany Sravan Kumar | CFO | S - Sale | $27.10 | -6,294 | 73,706 | -8% | -$170,567 | ||||||
2025-12-31 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $27.10 | -1,254 | 115,667 | -1% | -$33,983 | ||||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Nickson Philip | Chief Business, Legal Officer | S - Sale+OE | $15.17 | -3,155 | 60,845 | -5% | -$47,861 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $15.17 | -2,629 | 62,371 | -4% | -$39,882 | |||||
| D | 2026-01-02 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $7.60 | -10,312 | 88,020 | -10% | -$78,371 | |||||
2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $15.17 | -1,039 | 22,693 | -4% | -$15,762 | ||||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale+OE | $15.17 | -10,135 | 624,403 | -2% | -$153,748 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale+OE | $15.17 | -3,155 | 75,026 | -4% | -$47,861 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $15.17 | -3,155 | 67,845 | -4% | -$47,861 | |||||
2026-01-02 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.93 | -22,000 | 1,166,391 | -2% | -$130,383 | ||||||
2025-12-31 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | S - Sale | $46.69 | -9,743 | 23,928 | -29% | -$454,891 | ||||||
| D | 2025-12-31 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $78.06 | -30,000 | 663,077 | -4% | -$2,341,939 | |||||
| DM | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $40.56 | -72,500 | 10,503 | -87% | -$2,940,799 | |||||
| D | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.56 | -45,000 | 0 | -100% | -$1,825,355 | |||||
| DM | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $40.41 | -15,000 | 12,965 | -54% | -$606,173 | |||||
| AM | 2025-12-26 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale | $0.62 | -20,657,300 | 244,445,260 | -8% | -$12,771,580 | |||||
| M | 2025-12-26 | SCLX | Scilex Holding Co | Scilex Holding Co | 10% | S - Sale | $0.62 | -20,657,300 | 244,445,260 | -8% | -$12,771,580 | |||||
2025-12-29 | RXRX | Recursion Pharmaceuticals, Inc. | Taylor Ben R | CFO | S - Sale | $4.18 | -21,383 | 761,550 | -3% | -$89,381 | ||||||
2025-12-24 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $82.51 | -6,000 | 859,741 | -1% | -$495,089 | ||||||
2025-12-29 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $124.83 | -10,000 | 566,698 | -2% | -$1,248,272 | ||||||
2025-12-29 | ENTX | Entera Bio Ltd. | Toledano Miranda Jayne | CEO | P - Purchase | $1.81 | +11,000 | 426,575 | +3% | +$19,912 | ||||||
| D | 2025-12-22 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.50 | -4,394 | 318,478 | -1% | -$76,895 | |||||
2025-12-23 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance | S - Sale | $47.92 | -11,623 | 13,534 | -46% | -$556,972 | ||||||
2025-12-26 | QNCX | Quince Therapeutics, Inc. | Benatti Luca | Dir | S - Sale | $3.47 | -50,000 | 39,179 | -56% | -$173,500 | ||||||
| D | 2025-12-22 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | Chief R, D Commercial Officer | S - Sale+OE | $4.41 | -124,403 | 611,135 | -17% | -$548,592 | |||||
2025-12-23 | CGEM | Cullinan Therapeutics, Inc. | Ahmed Nadim | Pres, CEO | S - Sale | $10.01 | -9,922 | 420,699 | -2% | -$99,319 | ||||||
2025-12-22 | IPSC | Century Therapeutics, Inc. | Cowan Chad | Chief Scientific Officer | P - Purchase | $0.85 | +58,060 | 1,055,784 | +6% | +$49,252 | ||||||
2025-12-24 | IMA | Imagenebio, Inc. | Slattery Joseph P | Dir | P - Purchase | $5.99 | +16,000 | 16,000 | New | +$95,840 | ||||||
2025-12-24 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $7.50 | -1,000,000 | 2,744,741 | -27% | -$7,500,000 | ||||||
| D | 2025-12-20 | FDMT | 4D Molecular Therapeutics, Inc. | Gupta Ashoo | VP, Finance, Controller | S - Sale+OE | $8.68 | -389 | 46,359 | -1% | -$3,377 | |||||
2025-12-19 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $80.00 | -1,500 | 193,371 | -1% | -$120,000 | ||||||
| M | 2025-12-19 | TCRX | Tscan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $0.90 | +161,801 | 15,956,564 | +1% | +$145,526 | |||||
2025-12-22 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale | $55.95 | -10,000 | 6,767 | -60% | -$559,549 | ||||||
2025-12-22 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale | $7.65 | -21,773 | 398,751 | -5% | -$166,563 | ||||||
2025-12-22 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $34.56 | -273 | 166,639 | 0% | -$9,434 | ||||||
2025-12-22 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $34.56 | -324 | 144,680 | 0% | -$11,196 | ||||||
| D | 2025-12-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $34.56 | -1,605 | 874,313 | 0% | -$55,462 | |||||
2025-12-19 | PLX | Protalix Biotherapeutics, Inc. | Bashan Dror | Pres, CEO | P - Purchase | $1.81 | +56,000 | 2,532,934 | +2% | +$101,360 | ||||||
2025-12-19 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $10.01 | -1,345 | 132,635 | -1% | -$13,463 | ||||||
2025-12-18 | KYTX | Kyverna Therapeutics, Inc. | Seidenberg Beth C | Dir | P - Purchase | $7.50 | +133,333 | 4,673,891 | +3% | +$999,998 | ||||||
2025-12-18 | KYTX | Kyverna Therapeutics, Inc. | Westlake Biopartners Opportunity Fund I, L.P. | 10% | P - Purchase | $7.50 | +133,333 | 4,657,257 | +3% | +$999,998 | ||||||
| D | 2025-11-01 | HALO | Halozyme Therapeutics, Inc. | Caudill Cortney | SVP, COO | S - Sale+OE | $65.19 | -4,263 | 12,737 | -25% | -$277,905 | |||||
| D | 2025-12-19 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.50 | -40,000 | 913,839 | -4% | -$180,000 | |||||
2025-12-18 | CGEM | Cullinan Therapeutics, Inc. | Sumer Jacquelyn L | GC | S - Sale | $9.67 | -3,480 | 135,432 | -3% | -$33,652 | ||||||
2025-12-18 | CGEM | Cullinan Therapeutics, Inc. | Jones Jeffrey Alan | Chief Medical Officer | S - Sale | $9.67 | -4,632 | 169,532 | -3% | -$44,791 | ||||||
2025-12-18 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $9.67 | -2,898 | 133,980 | -2% | -$28,024 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Rakin Kevin | Dir, 10% | P - Purchase | $0.52 | +50,000 | 5,155,098 | +1% | +$25,995 | ||||||
| D | 2025-12-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $10.90 | -1,635 | 3,594 | -31% | -$17,822 | |||||
2025-12-18 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $23.00 | +2,608,696 | 18,358,772 | +17% | +$60,000,008 | ||||||
2025-12-18 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $26.91 | -10,813 | 149,930 | -7% | -$290,943 | ||||||
| M | 2025-12-17 | DBVT | Dbv Technologies S.A. | Epic Bpifrance | Member of 10% owner group | S - Sale | $4.60 | -3,369,093 | 7,529,502 | -31% | -$15,484,143 | |||||
2025-12-16 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $44.09 | -1,006 | 32,908 | -3% | -$44,352 | ||||||
2025-12-17 | RGEN | Repligen Corp | Dawes Karen A | Dir | S - Sale | $161.00 | -275 | 91,821 | 0% | -$44,275 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $76.82 | -2,688 | 47,884 | -5% | -$206,484 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $76.82 | -15,394 | 937,367 | -2% | -$1,182,526 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $76.82 | -5,447 | 278,600 | -2% | -$418,423 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $76.82 | -4,847 | 141,053 | -3% | -$372,333 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $77.09 | -3,104 | 108,065 | -3% | -$239,289 | ||||||
2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $80.10 | -7,397 | 38,958 | -16% | -$592,500 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Colpman David | Dir | P - Purchase | $0.51 | +12,500 | 31,098 | +67% | +$6,375 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Makes Brigid | Dir | P - Purchase | $0.52 | +25,000 | 27,000 | >999% | +$13,000 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Mills C Randal | Pres, CEO | P - Purchase | $0.51 | +3,000 | 379,204 | +1% | +$1,530 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Ferguson Matthew | CFO | P - Purchase | $0.53 | +60,000 | 447,110 | +15% | +$31,800 | ||||||
| D | 2025-12-15 | KYTX | Kyverna Therapeutics, Inc. | Walker Karen Marie | CTO | S - Sale+OE | $12.20 | -23,998 | 22,636 | -51% | -$292,776 | |||||
| D | 2025-12-15 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $15.57 | -113,890 | 318,478 | -26% | -$1,773,267 | |||||
| M | 2025-12-16 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.31 | +1,100 | 267,966 | 0% | +$1,444 | |||||
| D | 2025-12-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $82.16 | -27,563 | 0 | -100% | -$2,264,480 | |||||
| DM | 2025-12-15 | NBIX | Neurocrine Biosciences Inc | Norwalk Leslie V | Dir | S - Sale+OE | $152.78 | -6,190 | 6,239 | -50% | -$945,702 | |||||
2025-12-15 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale | $81.26 | -22,946 | 128,832 | -15% | -$1,864,678 | ||||||
| D | 2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Lin Elizabeth Yeu | Chief Medical Officer | S - Sale+OE | $79.50 | -2,078 | 40,341 | -5% | -$165,201 | |||||
2025-12-16 | DTIL | Precision Biosciences Inc | Germano Geno J | Dir | P - Purchase | $4.72 | +3,000 | 23,883 | +14% | +$14,160 | ||||||
2025-12-16 | DTIL | Precision Biosciences Inc | Frankel Stanley | Dir | P - Purchase | $4.70 | +2,700 | 19,478 | +16% | +$12,690 | ||||||
2025-12-15 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.97 | +1,381 | 23,346 | +6% | +$6,864 | ||||||
| D | 2025-10-07 | SRRK | Scholar Rock Holding Corp | Akkaraju Srinivas | Dir | P - Purchase | $39.92 | +29,599 | 6,918,784 | 0% | +$1,181,634 | |||||
| D | 2025-12-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $19.79 | -21,000 | 3,732,233 | -1% | -$415,590 | |||||
2025-12-12 | CLDI | Calidi Biotherapeutics, Inc. | Camaisa Allan | Dir | S - Sale | $1.46 | -850 | 76,952 | -1% | -$1,237 | ||||||
2025-12-12 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | P - Purchase | $0.58 | +52,000 | 3,322,990 | +2% | +$30,352 | ||||||
2025-12-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $122.00 | -3,000 | 153,503 | -2% | -$366,000 | ||||||
2025-12-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $122.00 | -3,000 | 106,221 | -3% | -$366,000 | ||||||
| D | 2025-12-15 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $8.89 | -736 | 7,488 | -9% | -$6,540 | |||||
| M | 2025-12-12 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.23 | -3,143 | 136,878 | -2% | -$38,433 | |||||
2025-12-15 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale | $7.65 | -21,210 | 315,726 | -6% | -$162,257 | ||||||
2025-12-15 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $6.00 | -3,187 | 1,209,948 | 0% | -$19,122 | ||||||
| D | 2025-12-11 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale+OE | $29.49 | -23,853 | 6,856,164 | 0% | -$703,306 | |||||
2025-12-10 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $75.38 | -20,000 | 1,212,987 | -2% | -$1,507,657 | ||||||
| D | 2025-12-10 | CDTX | Cidara Therapeutics, Inc. | Ward Shane | COO, CLO | S - Sale+OE | $220.08 | -9,959 | 25,033 | -28% | -$2,191,747 | |||||
2025-12-10 | ADPT | Adaptive Biotechnologies Corp | Hershberg Robert | Dir | S - Sale | $16.00 | -22,968 | 46,722 | -33% | -$367,488 | ||||||
| M | 2025-12-10 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $91.72 | -236,588 | 685,393 | -26% | -$21,699,044 | |||||
| D | 2025-12-09 | REPL | Replimune Group, Inc. | Dhingra Kapil | Dir | S - Sale+OE | $10.40 | -3,169 | 0 | -100% | -$32,958 | |||||
2025-12-11 | KYMR | Kymera Therapeutics, Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $86.00 | +2,005,813 | 7,955,916 | +34% | +$172,499,918 | ||||||
2025-12-09 | MRNA | Moderna, Inc. | Hussain Abbas | Dir | S - Sale | $27.60 | -504 | 1,515 | -25% | -$13,910 | ||||||
2025-12-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.53 | -257 | 404,874 | 0% | -$137 | ||||||
2025-12-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $0.53 | -526 | 483,755 | 0% | -$280 | ||||||
2025-12-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.88 | -398 | 145,004 | 0% | -$13,085 | ||||||
| D | 2025-12-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.88 | -2,255 | 875,918 | 0% | -$74,140 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |